In vitro and in vivo correlation for lipid-based formulations: Current status and future perspectives.

Autor:	Huang Y; Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China., Yu Q; Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China., Chen Z; Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China., Wu W; Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.; Key Laboratory of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai 201203, China., Zhu Q; Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China., Lu Y; Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.; Key Laboratory of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai 201203, China.
Jazyk:	angličtina
Zdroj:	Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2021 Aug; Vol. 11 (8), pp. 2469-2487. Date of Electronic Publication: 2021 Mar 21.
DOI:	10.1016/j.apsb.2021.03.025
Abstrakt:	Lipid-based formulations (LBFs) have demonstrated a great potential in enhancing the oral absorption of poorly water-soluble drugs. However, construction of in vitro and in vivo correlations (IVIVCs) for LBFs is quite challenging, owing to a complex in vivo processing of these formulations. In this paper, we start with a brief introduction on the gastrointestinal digestion of lipid/LBFs and its relation to enhanced oral drug absorption; based on the concept of IVIVCs, the current status of in vitro models to establish IVIVCs for LBFs is reviewed, while future perspectives in this field are discussed. In vitro tests, which facilitate the understanding and prediction of the in vivo performance of solid dosage forms, frequently fail to mimic the in vivo processing of LBFs, leading to inconsistent results. In vitro digestion models, which more closely simulate gastrointestinal physiology, are a more promising option. Despite some successes in IVIVC modeling, the accuracy and consistency of these models are yet to be validated, particularly for human data. A reliable IVIVC model can not only reduce the risk, time, and cost of formulation development but can also contribute to the formulation design and optimization, thus promoting the clinical translation of LBFs. (© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu